Skip to main content
Back
Watch Compare

REGENXBIO Inc.

Data quality: 100%
RGNX
Nasdaq Manufacturing Chemicals
$8.91
▲ $0.24 (2.71%)
Mkt Cap: 459.61 M
Price
$8.91
Mkt Cap
459.61 M
Day Range
$8.41 — $8.97
52-Week Range
$5.15 — $16.19
Volume
231,431
Open $8.54
50D / 200D Avg
$9.27
3.89% below
50D / 200D Avg
$10.49
15.10% below

Quick Summary

Key Takeaways

Revenue declined -22.41% annually over 5 years
Negative free cash flow of -126.38 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 126.95%
Capital efficient — spends only 1.42% of revenue on capex

Growth

Revenue Growth (5Y)
-22.41%
Below sector avg (1.82%)
Revenue (1Y)104.54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-103.37%
Below sector avg (-53.47%)
ROIC-29.54%
Net Margin-113.75%
Op. Margin-94.58%

Safety

Debt / Equity
N/A
Current Ratio2.66
Interest Coverage-3.58

Valuation

PE (TTM)
-2.37
Below sector avg (-1.47)
P/B Ratio2.85
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -2.4 -1.5
P/B 2.9 1.6
ROE % -103.4 -53.5
Net Margin % -113.8 -41.5
Rev Growth 5Y % -22.4 1.8
D/E — 0.3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0.67% weight
DLHAX DLHAX
0.31% weight
DLRHX DLRHX
0.31% weight
DLHIX DLHIX
0.31% weight
BDSAX BDSAX
0.13% weight
BDSCX BDSCX
0.13% weight
BDSKX BDSKX
0.13% weight
BDSIX BDSIX
0.13% weight
PSGIX PSGIX
0.10% weight
CSGEX CSGEX
0.10% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 104.54% Revenue Growth (3Y) 37.43%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -22.41% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 170.44 M Net Income (TTM) -193.88 M
ROE -103.37% ROA -35.05%
Gross Margin N/A Operating Margin -94.58%
Net Margin -113.75% Free Cash Flow (TTM) -126.38 M
ROIC -29.54% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.66
Interest Coverage -3.58 Asset Turnover 0.31
Working Capital 207.40 M Tangible Book Value 161.45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.37 Forward P/E N/A
P/B Ratio 2.85 P/S Ratio 2.70
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -27.50%
Market Cap 459.61 M Enterprise Value 400.81 M
Per Share
EPS (Diluted TTM) -3.76 Revenue / Share 3.30
FCF / Share -2.45 OCF / Share -2.40
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.42% FCF Conversion 65.18%
SBC-Adj. FCF -162.45 M Growth Momentum 126.95

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 170.44 M 83.33 M 90.24 M 112.72 M 470.35 M
Net Income -193.88 M -227.10 M -263.49 M -280.32 M 127.84 M
EPS (Diluted) -3.76 -4.59 -6.02 -6.50 2.91
Gross Profit — — — — —
Operating Income -161.20 M -233.35 M -268.13 M -262.88 M 159.98 M
EBITDA — — — — —
R&D Expenses 228.30 M 208.52 M 232.27 M 242.45 M 181.44 M
SG&A Expenses — — — — —
D&A 15.62 M 16.22 M 17.32 M 12.91 M 9.56 M
Interest Expense 45.01 M 12.66 M 6.86 M 23.25 M 26.28 M
Income Tax 0.0 -152,000.0 -152,000.0 -84,000.0 13.41 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 453.03 M 465.99 M 573.97 M 833.27 M 1.11 B
Total Liabilities 350.30 M 206.34 M 262.23 M 317.07 M 349.61 M
Shareholders' Equity 102.73 M 259.65 M 311.74 M 516.20 M 764.30 M
Total Debt — — — — —
Cash & Equivalents 34.47 M 57.53 M 34.52 M 96.95 M 345.21 M
Current Assets 281.28 M 278.00 M 334.97 M 415.98 M 518.83 M
Current Liabilities 118.10 M 103.19 M 130.27 M 130.43 M 130.47 M